SNP genotypes | Total (n) | Adverse events | Â | OR (95% CI) | |
---|---|---|---|---|---|
Yes (n, %) | No (n) | ||||
rs3743527 | Â | Myelosuppression | Â | Â | Â |
 CC | 63 | 48 (76.2) | 15 |  | 1.00 (reference) |
 TC | 108 | 85 (78.7) | 23 | 0.703 | 1.155 (0.51–2.422) |
 TT | 35 | 34 (97.1) | 1 | 0.007 | 10.625 (1.339–84.317) |
 TC+TTa | 143 | 119 (83.2) | 24 | 0.236 | 1.549 (0.749–3.206) |
rs212091 | Â | Myelosuppression | Â | Â | Â |
 AA | 122 | 107 (87.7) | 15 |  | 1.00 (reference) |
 AG | 72 | 51 (70.8) | 21 | 0.003 | 0.340 (0.162–0.715) |
 GG | 12 | 9 (75.0) | 3 | 0.431 | 0.421 (0.102–1.729) |
 AG+GGa | 84 | 60 (71.4) | 24 | 0.003 | 0.350 (0.171–0.719) |
rs212090 | Â | Gastrointestinal reaction | Â | Â | Â |
 TT | 135 | 37 (27.4) | 98 |  | 1.00 (reference) |
 AT | 63 | 29 (46.0) | 34 | 0.010 | 2.259 (1.211–4.213) |
 AA | 8 | 0 (0) | 8 | 0.192 | – |
 AA+ATa | 71 | 29 (40.8) | 42 | 0.049 | 1.829 (0.998–3.35) |
rs9024 | Â | Cardiotoxicity | Â | Â | Â |
 GG | 123 | 2 (1.6) | 121 |  | 1.00 (reference) |
 GA | 69 | 7 (10.1) | 62 | 0.020 | 6.831 (1.378–33.866) |
 AA | 14 | 2 (14.3) | 12 | 0.052 | 10.083 (1.301–78.151) |
 GA+AAa | 83 | 9 (10.8) | 74 | 0.010 | 7.358 (1.547–34.989) |